Updated:
GlaxoSmithKline Group Pension Fund
GlaxoSmithKline Group Pension Fund was established to administer defined benefit schemes for the legacy GlaxoSmithKline workforce. The fund covers participants...
GlaxoSmithKline Group Pension Fund
GlaxoSmithKline Group Pension Fund was established to administer defined benefit schemes for the legacy GlaxoSmithKline workforce. The fund covers participants in the United Kingdom, the United States and additional jurisdictions. The pension fund allocates across public and private markets. Confirmed strategies include buyout and early-stage commitments. Geographic exposure spans North America and Europe. The Trustee mandates ESG integration and supports engagement with portfolio companies. The fund reports $13.8 billion in assets. It maintains no disclosed additional offices or adjacent philanthropic vehicles. No operational events from the last 24 months appear in available records. The fund functions strictly as a corporate pension vehicle tied to GlaxoSmithKline employment liabilities rather than an independent allocator.
General information
Firm type
Corporate Investor
Year founded
1715
AUM
13849 (Altss estimate)
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
980 Great West Road, Middlesex, United Kingdom
Sector focus
Frequently asked questions
Who runs investment decisions at GlaxoSmithKline Group Pension Fund?
Investment decisions rest with appointed external managers under Trustee oversight. The Trustee sets policy including ESG requirements.
Does GlaxoSmithKline Group Pension Fund participate in fund commitments or only direct deals?
The fund uses both fund commitments and direct strategies. Records show activity in buyout and early-stage vehicles.
What investment stages does GlaxoSmithKline Group Pension Fund typically target?
The fund targets buyout and early-stage opportunities alongside traditional fixed income and equity holdings.
Where does the underlying wealth come from?
Assets derive from corporate contributions and investment returns supporting defined benefit liabilities of GlaxoSmithKline employees.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: